Supplementary Materials and Methods, Tables ST1-13 from Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
Year: 2023
Type: supplementary-materials
Abstract: Supplementary materials and Methods, Tables ST1-13. Table ST1: Baseline clinical characteristics of patients in IMPACT Table ST2: Baseline clinical characteristics of patients in ProACT. Table ST3: Increase in levels of IgG against candidate antigens at weeks 2 and 22 in IMPACT as measured with ProtoArray Table ST4: Protein reagents used in Luminex xMAP assays. Table ST5: Overlap of the number of patients who were IgG responders to different antigens at week 10 after treatment in the sipuleucel-T arm of IMPACT. Table ST6: Evaluation of IgG responses to candidate antigens at week 12 in ProACT using Luminex xMAP. Table ST7: Association of post-treatment changes in serum levels of IgG at week 10 with OS in the sipuleucel-T arm of IMPACT. Table ST8: Comparison of OS in sipuleucel-T-treated IgG responders and IgG non-responders at week 10 with that in control patients in IMPACT. Table ST9: Evaluation of IgG responses against candidate antigens at weeks 2 and 22 in IMPACT using Luminex xMAP. Table ST10: Assessment of IgG responses against candidate antigens at weeks 4 and 20 in ProACT using Luminex xMAP. Table ST11: Overlap of the number of sipuleucel-T-treated patients who were IgG responders to antigens across the post-treatment time points in IMPACT Table ST12: Association of changes in serum IgG levels with OS at week 2 or 22 in the sipuleucel-T arm of IMPACT. Table ST13: Comparison of OS in sipuleucel-T-treated IgG responders and IgG non-responders with that in control patients at weeks 2 and 22 in IMPACT.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361884652